United Therapeutics (UTHR) Long-Term Deferred Tax (2016 - 2025)
United Therapeutics (UTHR) has disclosed Long-Term Deferred Tax for 17 consecutive years, with $357.7 million as the latest value for Q4 2025.
- Quarterly Long-Term Deferred Tax fell 21.97% to $357.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $357.7 million through Dec 2025, down 21.97% year-over-year, with the annual reading at $357.7 million for FY2025, 21.97% down from the prior year.
- Long-Term Deferred Tax hit $357.7 million in Q4 2025 for United Therapeutics, up from $354.9 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $458.4 million in Q4 2024 to a low of $261.9 million in Q4 2021.
- Historically, Long-Term Deferred Tax has averaged $342.7 million across 5 years, with a median of $326.6 million in 2022.
- Biggest five-year swings in Long-Term Deferred Tax: grew 25.12% in 2022 and later decreased 21.97% in 2025.
- Year by year, Long-Term Deferred Tax stood at $261.9 million in 2021, then rose by 25.12% to $327.7 million in 2022, then grew by 20.48% to $394.8 million in 2023, then rose by 16.11% to $458.4 million in 2024, then fell by 21.97% to $357.7 million in 2025.
- Business Quant data shows Long-Term Deferred Tax for UTHR at $357.7 million in Q4 2025, $354.9 million in Q3 2025, and $456.2 million in Q2 2025.